Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988439 · ClinicalTrials.gov registry record · Phase 4
A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis
A Phase 4 study of Psoriasis, sponsored by Bausch Health Americas.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
- 9
- Study locations
NCT03988439: Recruiting Phase 4 study of Psoriasis, sponsored by Bausch Health Americas.
NCT03988439 is a Phase 4 study of Psoriasis that is actively recruiting participants, run by Bausch Health Americas. The registered enrollment target is 45 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (91% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03988439, a Phase 4 study of Psoriasis, is actively recruiting participants, sponsored by Bausch Health Americas.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study is to evaluate the safety, the systemic exposure, and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-118 lotion in pediatric participants with moderate to severe plaque psoriasis.
Primary Outcome
On Days 28-29, blood samples will be collected from each participant for the determination of plasma concentrations and PK parameters of IDP-118 lotion analytes.
Conditions Studied
Interventions
- DRUG IDP-118 Lotion
Study Locations (9)
Florida
- Bausch Site 7 - Doral
- Bausch Site 11 - Miami
Other
- Bausch Site 12 - Santo Domingo
- Bausch Site 2 - Panama City
Kentucky
- Bausch Site 3 - Louisville
Missouri
- Bausch Site 6 - Saint Joseph
Nevada
- Bausch Site 1 - Henderson
Texas
- Bausch Site 5 - San Antonio
Utah
- Bausch Site 4 - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2027-03 |
| Phase | Phase 4 |
What NCT03988439 shows while recruiting
NCT03988439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which IDP-118 Lotion is the first listed.
NCT03988439 lists 9 locations in 7 states (Florida, Other, Kentucky).
Frequently Asked Questions
What is clinical trial NCT03988439 about?
NCT03988439 is a clinical study titled "A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque Psoriasis". This study is to evaluate the safety, the systemic exposure, and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-118 lotion in pediatric participants with moderate to severe plaque psoriasis.
What is the current status of trial NCT03988439?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2021-03-24. Estimated completion is 2027-03.
What conditions does trial NCT03988439 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03988439?
The interventions under investigation include: IDP-118 Lotion (DRUG).
Who is sponsoring clinical trial NCT03988439?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03988439 being conducted?
This trial has 9 study locations across Florida, Kentucky, Missouri, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03988439's enrollment target sits among peer trials
45 79th of 125 higher than 46 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Duobrii in Combination With Biologics
RECRUITING · Phase 4
-
Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics
RECRUITING · Phase 4
-
ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.
RECRUITING · Phase 4
-
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
RECRUITING · Phase 4
-
Taltz in Combination With Enstilar for Psoriasis
RECRUITING · Phase 4
-
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI